A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2

Judith B. Vanhorne, Scott D. Andrew, Karen J. Harrison, Sherryl A M Taylor, Bradley Thomas, Thomas J. McDonald, Peter J. Ainsworth, Lois M. Mulligan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRα4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRα4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRα4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRα4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRα4 isoform expression that includes both activating and inhibiting co-receptors for RET.

Original languageEnglish
Pages (from-to)1091-1097
Number of pages7
JournalOncogene
Volume24
Issue number6
DOIs
Publication statusPublished - 03 Feb 2005

Fingerprint

Multiple Endocrine Neoplasia
Multiple Endocrine Neoplasia Type 2a
Mutation
Protein Isoforms
Glial Cell Line-Derived Neurotrophic Factor Receptors
Phenotype
Reading Frames
Proto-Oncogenes
Genes
Thyroid Gland
Ligands
Gene Expression
Membranes

Cite this

Vanhorne, J. B., Andrew, S. D., Harrison, K. J., Taylor, S. A. M., Thomas, B., McDonald, T. J., ... Mulligan, L. M. (2005). A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2. Oncogene, 24(6), 1091-1097. https://doi.org/10.1038/sj.onc.1207826
Vanhorne, Judith B. ; Andrew, Scott D. ; Harrison, Karen J. ; Taylor, Sherryl A M ; Thomas, Bradley ; McDonald, Thomas J. ; Ainsworth, Peter J. ; Mulligan, Lois M. / A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2. In: Oncogene. 2005 ; Vol. 24, No. 6. pp. 1091-1097.
@article{92607bd6210c4c88b47dff9be0cec653,
title = "A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2",
abstract = "Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRα4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRα4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRα4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRα4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRα4 isoform expression that includes both activating and inhibiting co-receptors for RET.",
keywords = "GFRα4, GFRA family, Multiple endocrine neoplasia type 2, Thyroid tumours",
author = "Vanhorne, {Judith B.} and Andrew, {Scott D.} and Harrison, {Karen J.} and Taylor, {Sherryl A M} and Bradley Thomas and McDonald, {Thomas J.} and Ainsworth, {Peter J.} and Mulligan, {Lois M.}",
note = "Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Oncogene. ISSNs: 0950-9232;",
year = "2005",
month = "2",
day = "3",
doi = "10.1038/sj.onc.1207826",
language = "English",
volume = "24",
pages = "1091--1097",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

Vanhorne, JB, Andrew, SD, Harrison, KJ, Taylor, SAM, Thomas, B, McDonald, TJ, Ainsworth, PJ & Mulligan, LM 2005, 'A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2', Oncogene, vol. 24, no. 6, pp. 1091-1097. https://doi.org/10.1038/sj.onc.1207826

A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2. / Vanhorne, Judith B.; Andrew, Scott D.; Harrison, Karen J.; Taylor, Sherryl A M; Thomas, Bradley; McDonald, Thomas J.; Ainsworth, Peter J.; Mulligan, Lois M.

In: Oncogene, Vol. 24, No. 6, 03.02.2005, p. 1091-1097.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2

AU - Vanhorne, Judith B.

AU - Andrew, Scott D.

AU - Harrison, Karen J.

AU - Taylor, Sherryl A M

AU - Thomas, Bradley

AU - McDonald, Thomas J.

AU - Ainsworth, Peter J.

AU - Mulligan, Lois M.

N1 - Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Oncogene. ISSNs: 0950-9232;

PY - 2005/2/3

Y1 - 2005/2/3

N2 - Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRα4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRα4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRα4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRα4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRα4 isoform expression that includes both activating and inhibiting co-receptors for RET.

AB - Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRα4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRα4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRα4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRα4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRα4 isoform expression that includes both activating and inhibiting co-receptors for RET.

KW - GFRα4

KW - GFRA family

KW - Multiple endocrine neoplasia type 2

KW - Thyroid tumours

UR - http://www.scopus.com/inward/record.url?scp=13944254036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944254036&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207826

DO - 10.1038/sj.onc.1207826

M3 - Article

C2 - 15592530

VL - 24

SP - 1091

EP - 1097

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -